UK Explains New ‘Reliance’ Routes To Approval Based On EU Dossiers
Firms Urged To File Early To Secure Timely Decisions
Executive Summary
Companies seeking marketing authorizations in the UK or Great Britain will be able to make use of two new “reliance” procedures offering regulatory assessment times of 67 days or less if their products have already gone through the EU centralized or decentralized approval systems.
You may also be interested in...
UK Early Access Granted For Argenx’s Generalized Myasthenia Gravis Treatment
Patients in the UK with generalized myasthenia gravis are being allowed to receive argenx’s yet-to-be approved drug efgartigimod.
Enhertu Nabs A First With UK Standalone Approval
The UK conditional approval of Daiichi Sankyo/AstraZeneca’s advanced breast cancer drug Enhertu was issued in accordance with “transitional provisions” that apply to drugs that received a positive opinion from the European Medicines Agency before the end of the Brexit transition period.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.